Loading...
Loading...
ARPO| Name | Value |
|---|---|
| Revenues | 23.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | 22.8M |
| Operating Expense | 53.5M |
| Operating I/L | -36.1M |
| Other Income/Expense | 0.0M |
| Interest Income | 2.7M |
| Pretax | -14.5M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -14.5M |
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company specializing in the research and development of treatments for ocular diseases. With a focus on developing innovative therapies, the company's lead product candidate, AKB-9778, is a small molecule activator of the Tie-2 pathway designed for the treatment of diabetic retinopathy. Additionally, the company's pipeline includes AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha for inflammatory bowel disease, and ARP-1536, a humanized monoclonal antibody targeting the same pathway as AKB-9778. Aerpio Pharmaceuticals generates revenue through the development and potential commercialization of these ocular disease treatments.
